<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245625
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DORAVIT 1.25MG/ML I.V. INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DROPERIDOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        188.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HIKMA ITALIA SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HIKMA ITALIA SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AD08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Doravit is a solution of droperidol for injection, which is used to prevent you feeling sick (nausea) or vomiting when you wake up after an operation or when you receive morphine based painkillers after an operation.</p><p>&nbsp;</p><p>Droperidol belongs to a group of antipsychotics called butyrophenone derivatives.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Doravit</strong></p><ul><li>Are allergic (hypersensitive) to the active ingredient droperidol, or any of the other ingredients in Doravit. (a list of these can be found in section 6 of this leaflet).</li><li>Are allergic to a group of medicines used to treat psychiatric disorders, called butyrophenones (e.g. haloperidol, triperidol, benperidol, melperone, domperidone)</li><li>Or anyone in your family have an abnormal electrocardiogram (ECG) heart tracing</li><li>Have low levels of potassium or magnesium in your blood</li><li>Have a pulse rate of less than 55 beats per minute (the doctor or nurse will check this), or are taking any medicines that could cause this to happen</li><li>Have a tumour in your adrenal gland (phaeochromocytoma)</li><li>Are in a coma</li><li>Have Parkinson&rsquo;s disease</li><li>Have severe depression.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Before you are given Doravit, you should tell your doctor or nurse if you:</p><ul><li>Have epilepsy, or a history of epilepsy</li><li>Have any heart problems or if you have any history of heart problems</li><li>Have a family history of sudden death</li><li>Have kidney problems (especially if you are on long-term dialysis)</li><li>Have lung disease and any breathing difficulties</li><li>Have prolonged sickness or diarrhoea</li><li>Are taking insulin</li><li>Are taking potassium-wasting diuretics i.e. water tablets (e.g. furosemide or bendroflumethiazide)</li><li>Are taking laxatives</li><li>Are taking glucocorticoids (a type of steroid hormone)</li><li>If you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots</li><li>Are or have been a heavy drinker (of alcohol).</li></ul><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Doravit</strong></p><p>Always tell your doctor or nurse if you are taking or have recently taken any other medicines including those you have obtained without a prescription, as a number of medicines cannot be mixed with droperidol.</p><p>&nbsp;</p><p>Do not take Doravit if you are taking any of the following medicines:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>What the medicine is used for</strong></p></td><td style="vertical-align:top"><p><strong>Medicine(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Heart conditions</p></td><td style="vertical-align:top"><p>Quinidine, disopyramide, procainamide, amiodarone or sotalol</p></td></tr><tr><td style="vertical-align:top"><p>Antibiotics</p></td><td style="vertical-align:top"><p>Erythromycin, clarithromycin, sparfloxacin</p></td></tr><tr><td style="vertical-align:top"><p>Allergies</p></td><td style="vertical-align:top"><p>Astemizole, terfenadine</p></td></tr><tr><td style="vertical-align:top"><p>Mental illnesses e.g. schizophrenia etc.</p></td><td style="vertical-align:top"><p>Chlorpromazine, haloperidol, melperone, phenothiazines, pimozide, thioridazine</p></td></tr><tr><td style="vertical-align:top"><p>Malaria</p></td><td style="vertical-align:top"><p>Chloroquine, halofantrine</p></td></tr><tr><td style="vertical-align:top"><p>Heartburn</p></td><td style="vertical-align:top"><p>Cisapride</p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Pentamidine</p></td></tr><tr><td style="vertical-align:top"><p>Nausea (feeling sick) or vomiting</p></td><td style="vertical-align:top"><p>Domperidone</p></td></tr><tr><td style="vertical-align:top"><p>Opiod dependence; pain</p></td><td style="vertical-align:top"><p>Methadone</p></td></tr></tbody></table><p>&nbsp;</p><p>Metoclopramide and other neuroleptics should be avoided when taking Doravit since the risk of movement disorders induces by these medicines is increased.</p><p>&nbsp;</p><p>Droperidol, the active ingredient in Doravit, can increase the effects of sedatives such as barbiturates, benzodiazepines and morphine based products. It can also increase the effects of medication used to lower high blood pressure (antihypertensives) and a number of other medicines e.g. certain antifungals, antivirals, and antibiotics. Some medicines may also increase the effects of droperidol e.g. cimetidine (for gastric ulcers), ticlopidine (to prevent blood-clotting) and mibefradil (for angina). If you are in any doubt please talk to your doctor or nurse.</p><p><strong>&nbsp;</strong></p><p><strong>Doravit with food and drink</strong></p><p>Avoid drinking any alcohol for 24 hours before and after being given Doravit.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant, inform your doctor who will decide if you should receive Doravit.</p><p>&nbsp;</p><p>If you are breast-feeding and are going to take Doravit then it is recommended that you receive only one administration of Doravit. Breast-feeding can be resumed on waking after your operation.</p><p>&nbsp;</p><p>Ask your doctor for advice before taking any medicine</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Droperidol has a major effect on the ability to drive and use machines. Do not drive or use machinery for at least 24 hours after taking Doravit.</p><p>&nbsp;</p><p><strong>Doravit</strong><strong> </strong><strong>contains sodium</strong></p><p>Doravit contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per 1 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Doravit will be given to you by your doctor by an injection into a vein.</p><p>&nbsp;</p><p>The amount of Doravit and the way in which it is given will depend on the situation. Your doctor will determine</p><p>how much Doravit you need based on a number of things including your weight, age and medical condition.</p><p>&nbsp;</p><p>The usual adult dosage is 0.625 to 1.25 mg, reduced to 0.625 mg for the elderly (over 65 years) and those with renal and kidney impairment. The dosage in children (2 to 11 years) and adolescents (12 to 18 years) is based on their body weight (10 to 50 microgram/kg) but up to a maximum of 1.25 mg. Doravit is not recommended in children below 2 years.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, please ask your doctor or nurse.</p><p>&nbsp;</p><p><strong>Instructions for use</strong></p><p><em>Opening the ampoule</em></p><p>1.&nbsp; Hold the ampoule between your thumb and index finger with the top of the ampoule showing.</p><p>2.&nbsp; With the other hand, grasp the upper part of the ampoule, with your index finger placed against the neck, and your thumb on the coloured point.</p><p>3.&nbsp; Keeping your thumb on the point, break the top of the ampoule with a sharp movement firmly holding the body of the ampoule in your hand. If you have any further questions on the use of this product, please ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact your doctor immediately if you experience any increase in your body temperature, muscle stiffness, tremor, rapid swelling of the face or throat, or if you get chest pains after having this medicine.</p><p>&nbsp;</p><p><strong><em>The following side effects have also been reported:</em></strong></p><p><strong>Common side effects (likely to affect less than 1 in 10 people and more than 1 in 100)</strong></p><ul><li>Drowsiness</li><li>Low blood pressure.</li></ul><p>&nbsp;</p><p><strong>Uncommon side effects (likely to affect less than 1 in 100 people and more than 1 in 1,000)</strong></p><ul><li>Anxiety</li><li>Rolling of the eyes</li><li>Fast heartbeat e.g. more than 100 beats per minute</li><li>Dizziness.</li></ul><p>&nbsp;</p><p><strong>Rare side effects (likely to affect less than 1 in 1,000 people and more than 1 in 10,000)</strong></p><ul><li>Serious allergic reaction known as anaphylaxis or anaphylactic shock</li><li>Confusion</li><li>Agitation</li><li>Irregular heartbeat</li><li>Rash</li><li>Neuroleptic malignant syndrome, symptoms include fever, sweating, salivation, muscle stiffness and tremors.</li></ul><p>&nbsp;</p><p><strong>Very rare side effects (likely to affect less than 1 in 10,000 people)</strong></p><ul><li>Blood disorders (usually diseases affecting red blood cells or platelets). Your doctor can advise you.</li><li>Change in mood towards sadness, anxiety, depression and irritability</li><li>Involuntary muscle movements</li><li>Convulsions or tremors</li><li>Heart attack (cardiac arrest)</li><li>Torsade de pointes (life-threatening irregular heartbeat)</li><li>Prolonged QT interval in ECG (a heart condition affecting the heartbeat)</li><li>Sudden death.</li></ul><p>&nbsp;</p><p><strong><em>Other side effects which may occur are:</em></strong></p><ul><li>Inappropriate anti-diuretic hormone secretion (too much of the hormone is released leading to excess water and low sodium levels in the body)</li><li>Hallucinations</li><li>Epileptic seizures</li><li>Parkinson&rsquo;s disease</li><li>Psychomotor hyperactivity</li><li>Coma</li><li>Fainting</li><li>Breathing difficulties</li><li>Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.</li></ul><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>The solution should be used immediately on first opening.</p><p><em>After dilution:</em> Chemical and physical in-use stability of 5 mg droperidol with 100 mg morphine sulphate in 50 ml of 0.9% sodium chloride has been demonstrated in plastic syringes for 14 days at 25&deg;C.</p><p>From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration. The product should be visually inspected prior to use and only clear solutions practically free from particles should be used.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is droperidol.</p><p>&nbsp;</p><p>Each 2 ml of Doravit 2.5 mg/2 ml Solution for Injection contains 2.5 mg droperidol.</p><p>&nbsp;</p><p>The other ingredients are tartaric acid, mannitol, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Doravit 2.5 mg/2 ml Solution for Injection is sterile, clear and colorless solution in 2 ml type I amber glass ampoules with white color break.

Pack size: 10 Ampoules (2 ml). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hikma Italia S.P.A.<br />Viale Certosa, 10<br />27100 Pavia, Italy<br />Tel: + (39-0382) 1751844/+ (39-0382) 1751801<br />Fax: + (39-0382) 422745</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2023; version number SA3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دورافيت محلول دروبيريدول للحقن، يستخدم لمنع الشعور بالإعياء (الغثيان) أو القيء عند الإفاقة بعد عملية جراحية أو عند أخذ مسكنات الألم التي تحتوي على المورفين بعد عملية جراحية.</p><p>&nbsp;</p><p dir="RTL">ينتمي دروبيريدول إلى مجموعة من مضادات الذهان تسمى مشتقات بوتيروفينون.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطائك دورافيت</strong></p><ul dir="rtl"><li>إذا كنت تعاني من تحسس (فرط حساسية) للمادة الفعّالة دروبيريدول، أو لأي من المواد الأخرى في تركيبة دورافيت. (يمكن العثور على قائمة بهذه المواد في القسم 6 من هذه النشرة).</li><li>إذا كنت تعاني من تحسس لمجموعة من الأدوية المستخدمة لعلاج الاضطرابات النفسية، تسمى بيوتيروفينون (مثل، هالوبيريدول، تريبيريدول، بينبيريدول، ميلبيرون، دومبيريدون)</li><li>أو يعاني أي شخص في عائلتك من متابعة غير طبيعية لمخطط كهربية القلب</li><li>إذا كنت تعاني من انخفاض مستويات البوتاسيوم أو المغنيسيوم في الدم</li><li>إذا كان معدل نبض القلب لديك أقل من 55 نبضة في الدقيقة (سيفحص الطبيب أو الممرض ذلك)، أو تتناول أي أدوية قد تسبب حدوث ذلك</li><li>إذا كنت تعاني من ورم في الغدة الكظرية (ورم القواتم)</li><li>إذا كنت في حالة غيبوبة</li><li>إذا كنت مصاباً بمرض باركنسون</li><li>إذا كنت تعاني من اكتئاب شديد.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">يجب أن تخبر طبيبك أو ممرضك قبل إعطائك دورافيت إذا:</p><ul dir="rtl"><li>كنت تعاني من الصرع، أو أصبت به من قبل</li><li>كنت تُعاني من أي مشاكل في القلب أو كان لديك تاريخ مسبق مع مشاكل القلب</li><li>كان لديك حالات موت مفاجئ في عائلتك</li><li>كنت تعاني من مشاكل في الكلى (خاصة إذا كنت تخضع لغسيل الكلى لفترة طويلة)</li><li>كنت تعاني من مرض رئوي وأي صعوبات في التنفس</li><li>كنت تعاني من مرض أو إسهال طويل الأمد</li><li>كنت تأخذ الأنسولين</li><li>كنت تأخذ مدرات البول التي تهدر البوتاسيوم، مثل أقراص الماء (على سبيل المثال، فوروسيميد أو بندروفلوميثيازيد)</li><li>كنت تأخذ مُلينات</li><li>كنت تأخذ مركبات غلوكوكورتيكويد (نوع من هرمون الستيرويد)</li><li>عانيت أنت أو أحد أفراد أسرتك في السابق من حالات تجلط الدم، حيث إن هذه الأدوية لها علاقة بتكوين التجلطات الدموية</li><li>كنت تتناول (المشروبات الكحولية) بكثرة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى </strong><strong>ودورافيت</strong></p><p dir="RTL">أخبر طبيبك أو الممرض دائماً إذا كنت تأخذ أو أخذت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي أخذتها بدون وصفة طبية، حيث لا يمكن أخذ عدد من الأدوية مع دروبيريدول.</p><p dir="RTL">لا تستخدم دورافيت إذا كنت تأخذ أي من الأدوية التالية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>سبب استخدام الدواء</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الدواء (الأدوية)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أمراض القلب</p></td><td style="vertical-align:top"><p dir="RTL">كوينيدين، ديسوبيراميد، بروكاييناميد، أميودارون، سوتالول</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">مضادات حيوية</p></td><td style="vertical-align:top"><p dir="RTL">إريثروميسين، كلاريثروميسين، سبارفلوكساسين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حالات الحساسية</p></td><td style="vertical-align:top"><p dir="RTL">أستيميزول، تيرفينادين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأمراض العقلية مثل انفصام الشخصية وما إلى ذلك.</p></td><td style="vertical-align:top"><p dir="RTL">كلوربرومازين، هالوبيريدول، ميلبيرون، فينوثيازين، بيموزيد، ثيوريدازين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الملاريا</p></td><td style="vertical-align:top"><p dir="RTL">كلوروكين، هالوفانترين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حرقة في المعدة</p></td><td style="vertical-align:top"><p dir="RTL">سيسابريد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدوى</p></td><td style="vertical-align:top"><p dir="RTL">بنتاميدين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غثيان (شعور بالمرض) أو قيء</p></td><td style="vertical-align:top"><p dir="RTL">دومبيريدون</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاعتماد على المسكّنات الأفيونية، الألم</p></td><td style="vertical-align:top"><p dir="RTL">ميثادون</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">يجب تجنب ميتوكلوبراميد ومضادات الذهان الأخرى عند أخذ دورافيت نظراً لزيادة مخاطر اضطرابات الحركة الناتجة عن هذه الأدوية.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يزيد دروبيريدول، وهو المادة الفعالة في دورافيت، من تأثيرات المهدئات مثل الباربيتورات، البنزوديازيبينات والمنتجات التي أساسها المورفين. يمكن أيضاً أن يزيد من تأثيرات الأدوية المستخدمة لخفض ضغط الدم المرتفع (خافضات ارتفاع ضغط الدم) وعدد من الأدوية الأخرى مثل بعض مضادات الفطريات ومضادات الفيروسات والمضادات الحيوية. قد يزيد بعض الأدوية أيضاً من تأثير دروبيريدول مثل سيميتيدين (لقرحة المعدة)، تيكلوبيدين (لمنع تخثر الدم) وميبفراديل (للذبحة الصدرية). إذا كان لديك أي شك، فيُرجى استشارة طبيبك أو الممرض.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>دورافيت مع الطعام والشراب</strong></p><p dir="RTL">تجنب شرب أي مشروبات كحولية لمدة 24 ساعة قبل إعطاء دورافيت وبعده.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حاملاً، أخبري طبيبك الذي سيقرر إذا ما كان يجب أن تتلقي دورافيت أم لا.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ مرضعاً وستأخذين دورافيت، فحينها ينصح بعدم إعطائكِ دورافيت سوى مرة واحدة. يمكن استئناف الرضاعة الطبيعية عند الاستيقاظ بعد العملية.</p><p>&nbsp;</p><p dir="RTL">اطلبي النصيحة من طبيبكِ قبل استخدام أية أدوية.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير دورافيت في القيادة واستخدام الآلات </strong></p><p dir="RTL">دروبيريدول له تأثير كبير على القدرة على القيادة واستخدام الآلات. تجنب قيادة السيارة أو استخدام الآلات لمدة 24 ساعة على الأقل بعد أخذ دورافيت.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي دورافيت</strong><strong> على الصوديوم</strong></p><p>يحتوي دورافيت على الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل 1 مللتر، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يعطيك طبيبك دورافيت عن طريق الحقن في الوريد.</p><p>&nbsp;</p><p dir="RTL">تعتمد كمية دورافيت وطريقة إعطاءه على الحالة. سيحدد طبيبك المقدار الذي تحتاجه من دورافيت بناءً على عدد من الأشياء منها وزنك، عمرك وحالتك الطبية.</p><p>&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين هي 0.625 إلى 1.25 ملغم، وتنخفض إلى 0.625 ملغم لكبار السن (فوق 65 عاماً) ومن يعانون من قصور كُلوي وكبدي. تعتمد الجرعة عند الأطفال (عامين إلى 11 عاماً) والمراهقين (12 إلى 18 عاماً) على وزن الجسم (10 إلى 50 ميكروغرام/كغم) ولكن بحد أقصى 1.25 ملغم. لا ينصح باستخدام دورافيت في الأطفال الأقل من عامين.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل الطبيب أو الممرض.</p><p>&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL"><em>فتح الأمبولة</em></p><p dir="RTL">1. أمسك الأمبولة بين إبهامك وسبابتك مع إظهار الجزء العلوي من الأمبولة.</p><p dir="RTL">2. وأمسك بيدك الأخرى الجزء العلوي من الأمبولة، بوضع سبابتك على رقبة الأمبولة، وإبهامك على النقطة الملونة.</p><p dir="RTL">3. حافظ على وضع إبهامك على النقطة، اكسر الجزء العلوي من الأمبولة بحركة سريعة مع الإمساك بجسم الأمبولة بقوة في يدك. إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، يُرجى سؤال الطبيب أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا عانيت من أي زيادة في درجة حرارة جسمك، تيبس العضلات، رعشة، تورم سريع في الوجه أو الحلق، أو إذا عانيت من آلام في الصدر بعد استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong><em>تم أيضاً الإبلاغ عن الآثار الجانبية التالية:</em></strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (من المحتمل أن تؤثر في أقل من شخص من بين كل 10 أشخاص وأكثر من شخص من بين كل 100 شخص)</strong></p><ul dir="rtl"><li>نعاس</li><li>انخفاض ضغط الدم.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (من المحتمل أن تؤثر في أقل من شخص من بين كل 100 شخص وأكثر من شخص من بين كل 1000 شخص)</strong></p><ul dir="rtl"><li>قلق</li><li>دوران العينين</li><li>سرعة نبض القلب، مثلاً، أكثر من 100 نبضة في الدقيقة</li><li>دوخة.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة (من المحتمل أن تؤثر في أقل من شخص من بين كل 1000 شخص وأكثر من شخص من بين كل 10000 شخص)</strong></p><ul dir="rtl"><li>رد فعل تحسسي خطير يعرف باسم التأق (الحساسية المفرطة) أو صدمة تأقية</li><li>اضطراب</li><li>تهيُّج</li><li>عدم انتظام نبضات القلب</li><li>طفح جلدي</li><li>المتلازمة الخبيثة للأدوية المضادة للذهان، ومن أعراضها الحمى، التعرق، سيلان اللعاب، تيبس العضلات والرعاش.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جداً (من المحتمل أن تؤثر في أقل من شخص من بين كل 10000 شخص)</strong></p><ul dir="rtl"><li>اضطرابات الدم (أمراض تصيب عادةً خلايا الدم الحمراء أو الصفائح الدموية). يمكن لطبيبك أن ينصحك.</li><li>تغير المزاج نحو الحزن، القلق، الاكتئاب والتهيج</li><li>حركات العضلات اللاإرادية</li><li>تشنجات أو رعشات</li><li>أزمة قلبية (توقف القلب)</li><li>تسارع نبضات القلب (عدم انتظام ضربات القلب المهددة للحياة)</li><li>طول فترة QT في تخطيط كهربية القلب (حالة قلبية تؤثر على ضربات القلب)</li><li>الموت المفاجئ.</li></ul><p>&nbsp;</p><p dir="RTL"><strong><em>تشمل الآثار الجانبية الأخرى التي قد تحدث:</em></strong></p><ul dir="rtl"><li>إفراز غير مناسب للهرمون المضاد لإدرار البول (يتم إفراز الكثير من الهرمون ما يؤدي إلى زيادة الماء وانخفاض مستويات الصوديوم في الجسم)</li><li>هلوسات</li><li>نوبات الصرع</li><li>مرض باركنسون</li><li>فرط النشاط النفسي</li><li>غيبوبة</li><li>الإغماء</li><li>صعوبات في التنفس</li><li>تجلط الدم في الأوردة وخاصة في الساقين (تشمل الأعراض تورم، ألم واحمرار في الساق)، والتي يمكنها أن تنتقل عن طريق الأوعية الدموية إلى الرئتين مما يتسبب في ألم في الصدر وصعوبة في التنفس. اطلب المساعدة الطبية فوراً عند ملاحظة أي من هذه الأعراض.</li></ul><p>&nbsp;</p><p dir="RTL">يرجى إخبار الطبيب، مقدم الرعاية الصحية أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة أو في حال ظهور أية آثار جانبية جديدة لم تذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يجب استخدام المحلول فور فتحه لأول مرة.</p><p dir="RTL"><em>بعد التخفيف:</em> تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام ﻟ 5 ملغم دروبيريدول مع 100 ملغم من كبريتات المورفين في 50 مللتر من 0.9% كلوريد الصوديوم في حقن بلاستيكية لمدة 14 يوم عند درجة حرارة 25&deg; مئوية.</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يجب استخدام المستحضر المخفف على الفور. في حالة عدم الاستخدام على الفور، تقع مسؤولية فترات التخزين أثناء الاستخدام وظروف التخزين قبل الاستخدام على المستخدم، ويجب ألا تزيد عادةً عن 24 ساعة عند درجة حرارة تتراوح بين 2 إلى 8&deg; مئوية، ما لم يكن التخفيف في ظروف تعقيم مُحكمة ومُعتمدة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة. يجب فحص المنتج بصرياً قبل استخدامه ولا تستخدم إلا المحاليل الصافية والخالية فعلياً من الجسيمات.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي دروبيريدول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل 2 مللتر من دورافيت 2.5 ملغم/2 مللتر محلول للحقن على 2.5 ملغم دروبيريدول.</p><p>&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي حمض الطرطريك، مانيتول، هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">دورافيت 2.5 ملغم/2 مللتر محلول للحقن هو محلول معقم، صافٍ وعديم اللون في أمبولات زجاجية كهرمانية اللون من النوع رقم واحد بحجم 2 مللتر مع موضع كسر بلون أبيض.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: 10 أمبولات (2 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة الحكمة إيطاليا المساهمة العامة المحدودة<br />طريق سيرتوزا، 10<br />27100 بافيا، إيطاليا<br />هاتف: 1751844 (0382-39) +/ 1751801 (0382-39) +<br />فاكس: 422745 (0382-39) +</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2023/08؛ رقم النسخة SA3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Doravit 2.5 mg/2 ml Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 2 ml contains 2.5 mg droperidol. 

Excipient with known effect: Sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection

Sterile, clear and colorless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Prevention and treatment of post-operative nausea and vomiting in adults and, as second line, in children (2 to 11 years) and adolescents (12 to 18 years).</li><li>Prevention of nausea and vomiting induced by morphine derivates during post-operative patient controlled analgesia (PCA) in adults.</li></ul><p>&nbsp;</p><p>Certain precautions are required when administering Doravit: see sections 4.2, 4.3, and 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous use.</p><p>&nbsp;</p><p><strong>Prevention and treatment of post-operative nausea and vomiting (PONV).</strong></p><p><em>Adults:</em>&nbsp;0.625 mg to 1.25 mg (0.25 to 0.5 ml).</p><p>&nbsp;</p><p><em>Elderly (over 65 years):&nbsp;</em>0.625 mg (0.25 ml).</p><p>&nbsp;</p><p><em>Renal/hepatic impairment:</em>&nbsp;0.625 mg (0.25 ml).</p><p><em>&nbsp;</em></p><p><u>Pediatric&nbsp;population</u></p><p><em>Children (2 to 11 years) and adolescents (12 to 18 years):</em>&nbsp;10 to 50 microgram/kg (up to a maximum of 1.25 mg).</p><p>&nbsp;</p><p><em>Children (below the age of 2 years):</em>&nbsp;not recommended.</p><p>&nbsp;</p><p>Administration of Doravit is recommended 30 minutes before the anticipated end of surgery. Repeat doses may be given every 6 hours as required.</p><p>&nbsp;</p><p>The dosage should be adapted to each individual case. The factors to be considered here include age body weight, use of other medicinal products, type of anaesthesia and surgical procedure.</p><p>&nbsp;</p><p><strong>Prevention of nausea and vomiting induced by morphine derivatives during post-operative patient controlled analgesia (PCA).</strong></p><p><em>Adults:</em>&nbsp;15 to 50 micrograms Doravit per mg of morphine, up to a maximum daily dose of 5 mg Doravit.</p><p><em>&nbsp;</em></p><p><em>Elderly (over 65 years), renal and hepatic impairment:</em>&nbsp;no data in PCA available.</p><p><em>&nbsp;</em></p><p><u>Pediatric&nbsp;population</u></p><p><em>Children (2 to 11 years) and adolescents (12 to 18 years):&nbsp;</em>not indicated in PCA.</p><p>&nbsp;</p><p>Continuous pulse oximetry should be performed in patients with identified or suspected risk of ventricular arrhythmia and should continue for 30 minutes following single i.v. administration.</p><p>&nbsp;</p><p>For instructions on dilution of the product before administration, see section 6.6.</p><p>&nbsp;</p><p>See also sections 4.3, 4.4 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Doravit is contraindicated in patients with:
•	Hypersensitivity to Doravit or to any of the excipients;
•	Hypersensitivity to butyrophenones;
•	Known or suspected prolonged QT interval (QTc of > 450 msec in females and > 440 msec in males). This includes patients with congenitally long QT interval, patients who have a family history of congenital QT prolongation and patients treated concomitantly with medicinal products known to have a risk of torsades de pointes through QT prolongation (see section 4.5);
•	Hypokalaemia or hypomagnesaemia;
•	Bradycardia (< 55 heartbeats per minute);
•	Known concomitant treatment leading to bradycardia;
•	Phaeochromocytoma;
•	Comatose states;
•	Parkinson's Disease;
•	Severe depression.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Central Nervous System</strong></p><p>Doravit may enhance CNS depression produced by other CNS-depressant drugs. Any patient subjected to anaesthesia and receiving potent CNS depressant medicinal products or showing symptoms of CNS depression should be monitored closely.</p><p>&nbsp;</p><p>Concomitant use of metoclopramide and other neuroleptics may lead to an increase in extrapyramidal symptoms and should be avoided (see section 4.5).</p><p>&nbsp;</p><p>Use with caution in patients with epilepsy (or a history of epilepsy) and conditions predisposing to epilepsy or convulsions.</p><p>&nbsp;</p><p><strong>Cardiovascular</strong></p><p>Mild to moderate hypotension and occasionally (reflex) tachycardia have been observed following the administration of droperidol. This reaction usually subsides spontaneously. However, should hypotension persist, the possibility of hypovolaemia should be considered and appropriate fluid replacement administered.</p><p>&nbsp;</p><p>Patients with, or suspected of having, the following risk factors for cardiac arrhythmia should be carefully evaluated prior to administration of Doravit:</p><ul><li>A history of significant cardiac disease including serious ventricular arrhythmia, second or third</li><li>Degree atrio-ventricular block, sinus node dysfunction, congestive heart failure, ischemic heart disease and left ventricular hypertrophy;</li><li>Family history of sudden death;</li><li>Renal failure (particularly when on chronic dialysis);</li><li>Significant chronic obstructive pulmonary disease and respiratory failure;</li><li>Risk factors for electrolyte disturbances, as seen in patients taking laxatives, glucocorticoids, potassium-wasting diuretics, in association with the administration of insulin in acute settings, or in patients with prolonged vomiting and/or diarrhoea.</li></ul><p>&nbsp;</p><p>Patients at risk for cardiac arrhythmia should have serum electrolytes and creatinine levels assessed and the presence of QT prolongation excluded prior to administration of Doravit.</p><p>&nbsp;</p><p>Continuous pulse oximetry should be performed in patients with identified or suspected risk of ventricular arrhythmia and should continue for 30 minutes following single i.v. administration.</p><p>&nbsp;</p><p><strong>General</strong></p><p>To prevent QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance (hypokalaemia and/or hypomagnesaemia) e.g. potassium-wasting diuretics, laxatives and glucocorticoids.</p><p>&nbsp;</p><p>Substances inhibiting the activity of cytochrome P450 iso-enzymes (CYP) CYP1A2, CYP3A4 or both could decrease the rate at which droperidol is metabolised and prolong its pharmacological action. Hence, caution is advised if droperidol is given concomitantly with strong CYP 1A2 and CYP3A4 inhibitors (see section 4.5).</p><p>&nbsp;</p><p>Patients who have, or are suspected of having, a history of alcohol abuse or recent high intakes, should be thoroughly assessed before Doravit is administered.</p><p>&nbsp;</p><p>In case of unexplained hyperthermia, it is essential to discontinue treatment, since this sign may be one of the elements of malignant syndrome reported with neuroleptics.</p><p>&nbsp;</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with droperidol and preventive measures undertaken.</p><p>&nbsp;</p><p>The dose should be reduced in the elderly and those with impaired renal and hepatic function (see section 4.2).</p><p><strong>&nbsp;</strong></p><p><strong>Doravit contains sodium</strong></p><p>Doravit contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per 1 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Contraindicated for concomitant use</strong></p><p>Medicinal products known to cause torsades de pointes through QT prolongation should not be concomitantly administered with Doravit. Examples include:</p><ul><li>Class IA antiarrhythmics e.g. quinidine, disopyramide, procainamide</li><li>Class III antiarrhythmics e.g. amiodarone, sotalol</li><li>Macrolide antibiotics e.g. erythromycin, clarithromycin</li><li>Fluoroquinolone antibiotics e.g. sparfloxacin</li><li>Antihistamines e.g. astemizole, terfenadine</li><li>Certain antipsychotic medications e.g. chlorpromazine, haloperidol, pimozide, thioridazine</li><li>Anti-malaria agents e.g. chloroquine, halofantrine</li><li>Cisapride, domperidone, methadone, pentamidine.</li></ul><p>&nbsp;</p><p>Concomitant use of medicinal products that induce extrapyramidal symptoms, e.g. metoclopramide and other neuroleptics, may lead to an increased incidence of these symptoms and should therefore be avoided.</p><p>&nbsp;</p><p>Consumption of alcoholic beverages and medicines should be avoided.</p><p>&nbsp;</p><p><strong>Caution is advised for concomitant use</strong></p><p>Caution is advised when Doravit is used with any other medication known to prolong the QT interval.</p><p>&nbsp;</p><p>To reduce the risk of QT prolongation, caution is necessary when patients are taking medicinal products likely to induce electrolyte imbalance (hypokalaemia and/or hypomagnesaemia) e.g. potassium-wasting diuretics, laxatives and glucocorticoids.</p><p>&nbsp;</p><p>Doravit may potentiate the action of sedatives (barbiturates, benzodiazepines, morphine derivatives). The same applies to antihypertensive agents, so that orthostatic hypotension may ensue. Like other sedatives, Doravit may potentiate respiratory depression caused by opioids.</p><p>&nbsp;</p><p>Since droperidol blocks dopamine receptors, it may inhibit the action of dopamine agonists, such as bromocriptine, lisuride, and of L-dopa.</p><p>&nbsp;</p><p>Substances inhibiting the activity of cytochrome P450 iso-enzymes (CYP) CYP1A2, CYP3A4 or both could decrease the rate at which droperidol is metabolised and prolong its pharmacological action. Hence, caution is advised if droperidol is given concomitantly with CYP1A2 inhibitors (e.g. ciprofloxacin, ticlopidine), CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, verapamil) or both (e.g. cimetidine, mibefradil).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>A limited amount of clinical data have shown no increase of malformative risk.</p><p>&nbsp;</p><p>Droperidol has not been shown to be teratogenic in rats. Animal studies are insufficient with respect to the effects on pregnancy and embryonal/foetal, parturition and postnatal development.</p><p>&nbsp;</p><p>In newborn babies from mothers under long-term treatment and high doses of neuroleptics, temporary neurological disturbances of extrapyramidal nature have been described. In practice, as a precautionary measure, it is preferable not to administer droperidol during pregnancy. In late pregnancy, if its administration is necessary, monitoring of the newborn&#39;s neurological functions is recommended.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>Neuroleptics of the butyrophenone type are known to be excreted in breast milk; treatment with droperidol should be limited to a single administration. Repeat administration is not recommended.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>For droperidol, there were no effects on fertility in studies conducted in male and female rats (see section 5.3). The clinical effect of droperidol on fertility has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Droperidol has major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Patients should not drive or operate a machine for 24 hours after Doravit administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported events during clinical experience are incidents of drowsiness and sedation. In addition, less frequent reports of hypotension, cardiac arrhythmias, neuroleptic malignant syndrome (NMS) and symptoms associated with NMS, plus movement disorders, such as dyskinesias, plus incidents of anxiety or agitation have occurred.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to &lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge;1/10,000 to &lt; 1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>&lt; 1/10,000</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic systems disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood dyscrasias</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction; Angioneurotic oedema; Hyper-sensitivity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Inappropriate anti-diuretic hormone secretion</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anxiety; Restlessness/ Akathisia;</p></td><td style="vertical-align:top"><p>Confusional states; Agitation</p></td><td style="vertical-align:top"><p>Dysphoria</p></td><td style="vertical-align:top"><p>Hallucinations</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Drowsiness</p></td><td style="vertical-align:top"><p>Dystonia; Oculogyration</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Extra- pyramidal disorder; Convulsions; Tremor</p></td><td style="vertical-align:top"><p>Epileptic fits; Parkinson&#39;s disease; Psychomotor hyperactivity; Coma</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia; Dizziness</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias, including ventricular arrhythmias</p></td><td style="vertical-align:top"><p>Cardiac arrest Torsade de pointes; Electrogram QT prolonged</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Broncho- spasm; Laryngospasm</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome (NMS)</p></td><td style="vertical-align:top"><p>Sudden death</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Symptoms potentially associated with NMS have occasionally been reported i.e. changes in body temperature, stiffness and fever. An alteration in mental status with confusion or agitation and altered consciousness, have been seen. Autonomic instability may manifest as tachycardia, fluctuating blood pressure, excessive sweating/salivation and tremor. In extreme cases NMS may lead to coma, or renal and/or hepato-biliary problems.</p><p>&nbsp;</p><p>Isolated cases of amenorrhoea, galactorrhoea, gynaecomastia, hyperprolactinaemia, and oligomenorrhoea have been associated with prolonged exposure in psychiatric indications.</p><p>&nbsp;</p><p>Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic medicinal products - frequency unknown.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>The manifestations of Doravit overdose are an extension of its pharmacologic actions. Symptoms of accidental overdose are psychic indifference with a transition to sleep, sometimes in association with lowered blood pressure.</p><p>&nbsp;</p><p>At higher doses or in sensitive patients, extrapyramidal disorders may occur (salivation, abnormal movements, sometimes muscle rigidity). Convulsions may occur at toxic doses.</p><p>&nbsp;</p><p>Cases of QT-interval prolongation, ventricular arrhythmias and sudden death have been reported rarely.</p><p><strong>&nbsp;</strong></p><p><strong>Treatment</strong></p><p>No specific antidote is known. However, when extrapyramidal reactions occur, an anticholinergic should be administered.</p><p>&nbsp;</p><p>Patients with Doravit overdose should be closely monitored for signs of QT interval prolongation. Factors which predispose to torsades de pointes, e.g. electrolyte disturbances (especially hypokalaemia or hypomagnesaemia) and bradycardia should be taken into consideration.</p><p>&nbsp;</p><p>Pronounced hypotension should be treated by boosting circulation volume and taking other appropriate measures. Clear airways and adequate oxygenation should be maintained; an oropharyngeal airway or endotracheal tube might be indicated.</p><p>&nbsp;</p><p>If required, the patient should be observed carefully for 24 hours or longer; body warmth and adequate fluid intake should be maintained.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic&nbsp;group: Butyrophenone derivates. ATC code: N05AD08.</strong></p><p><strong>&nbsp;</strong></p><p>Droperidol is a butyrophenone neuroleptic. Its pharmacologic profile is characterised mainly by dopamine-blocking and weak &alpha;1-adrenolytic effects. Droperidol is devoid of anticholinergic and antihistaminic activity.</p><p>&nbsp;</p><p>Droperidol&#39;s inhibitory action on dopaminergic receptors in the chemotrigger zone in the area postrema, gives it a potent antiemetic effect, especially useful for the prevention and treatment of postoperative nausea and vomiting and/or induced by opioid analgesics.</p><p>&nbsp;</p><p>At a dose of 0.15 mg/kg, droperidol induces a fall in mean blood pressure (MBP), due to a decrease in cardiac output in a first phase, and then subsequently due to a decrease in pre-load. These changes occur independently of any alteration in myocardial contractility or vascular resistance. Droperidol does not affect myocardial contractility or heart rate, therefore has no negative inotropic effect. Its weak &alpha;1-adrenergic blockade can cause a modest hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may also reduce the incidence of epinephrine-induced arrhythmia, but it does not prevent other forms of cardiac arrhythmia.</p><p>&nbsp;</p><p>Droperidol has a specific antiarrhythmic effect at a dose of 0.2 mg/kg by an effect on myocardial contractility (prolongation of the refractory period) and a decrease in blood pressure.</p><p>&nbsp;</p><p>Two studies (one placebo-controlled and one comparative active treatment-controlled) performed in the general anaesthesia setting and designed to better identify the QTc changes associated with postoperative nausea and vomiting treatment by small dose of droperidol (0.625 and 1.25 mg intravenous, and 0.75 mg intravenous, respectively) identified a QT interval prolongation at 3-6 min after administration of 0.625 and 1.25 mg droperidol (respectively 15 &plusmn;40 and 22 &plusmn;41 ms), but these changes did not differ significantly from that seen with saline (12 &plusmn;35 ms). There were no statistically significant differences amongst the droperidol and saline groups in the number of patients with greater than 10% prolongation in QTc versus baseline.</p><p>&nbsp;</p><p>There was no evidence of droperidol-induced QTc prolongation after surgery.</p><p>&nbsp;</p><p>No ectopic heartbeats were reported from the electrocardiographic records or 12-lead recordings during the perioperative period. The comparative active-treatment study with 0.75 mg intravenous droperidol identified a significant QTc interval prolongation (maximal of 17&plusmn;9ms at the second minute after droperidol injection when compared with pre-treatment QTc measurement), with the QTc interval significantly lower after the 90th minute.&rdquo;</p><p>&nbsp;</p><p><strong>PONV</strong></p><p>In a systematic review of 222 studies on prevention of PONV, the risk of PONV was decreased compared to placebo by RR (95% confidence interval) 0.65 (0.60-0.71) for nausea, 0.65 (0.61-0.70) for vomiting and by 0.62 (0.58-0.67) for nausea and vomiting combined.</p><p><strong>&nbsp;</strong></p><p>In a combined analysis of 2061 high risk PONV patients, 1.25mg droperidol was more effective than 4 mg ondansetron or 0.625 mg droperidol in preventing nausea (p&lt;0.05; absence of nausea 43%, 29%, 29% respectively), in preventing vomiting (complete response 0-24h 56%, 53%, 48%) and in reducing the need for rescue medication (26%, 34%, 32%).</p><p>&nbsp;</p><p><strong>Monotherapy</strong></p><p>A meta-analysis study examined data from 74 clinical trials involving 5351 patients who received 24 different regimens of droperidol and 3372 patients who received placebo or no treatment. The incidence of early (0-6 hours) and late PONV (0-24 hours) in adults and children was analysed (see table).</p><p>&nbsp;</p><p>Early and late outcomes after droperidol compared to placebo or no treatment. Percentages shown refer to incidence of nausea or vomiting.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Droperidol</strong></p><p><strong>Average (range) in %</strong></p></td><td style="vertical-align:top"><p><strong>Placebo/no treatment</strong></p><p><strong>Average (range) in %</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Early outcome (0-6 hours)</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>16 (3-41)</p></td><td style="vertical-align:top"><p>33 (15-80)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>14 (0-56)</p></td><td style="vertical-align:top"><p>29 (6-86)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Late outcome (0-24 hours)</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>45 (1-86)</p></td><td style="vertical-align:top"><p>58 (11&ndash;96)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>28 (4-83)</p></td><td style="vertical-align:top"><p>46 (12-97)</p></td></tr></tbody></table><p>&nbsp;</p><p>Droperidol was more efficacious than placebo or no treatment in preventing PONV in adults and in children.</p><p>&nbsp;</p><p><strong>Combination therapy</strong></p><p>A randomised study in 4123 patients assessed the effectiveness of single and combined antiemetic interventions in patients at high risk of PONV. Treatment included 1.25 mg of droperidol or no droperidol; 4 mg of ondansetron or no ondansetron; 4 mg of dexamethasone or no dexamethasone. The addition of further antiemetics reduced the incidence of PONV, corresponding to an approximate 26% reduction in relative risk of nausea and vomiting for each additional antiemetic. All antiemetics tested were equally effective.</p><p>&nbsp;</p><p><strong>PCA</strong></p><p>A systematic review of 14 studies involving 1117 patients receiving PCA was performed. Droperidol was used in 6 with a dose range of 0.017-0.17 mg/mg of morphine; 0.017-0.33 mg/bolus. The incidence of any emetic event in patients receiving placebo was 66% compared to 30% for patients receiving droperidol.</p><p><strong>&nbsp;</strong></p><p><strong>QTc</strong></p><p>In a placebo-controlled study, treatment with droperidol identified a QT interval prolongation at 3-6 min after administration of 0.625 and 1.25 mg droperidol (respectively 15 &plusmn; 40 and 22 &plusmn; 41 ms), but these changes did not differ significantly from that seen with placebo (12 &plusmn; 35 ms). There were no statistically significant differences compared to placebo in the number of patients with greater than 10% QTc prolongation. A second study with 0.75 mg intravenous droperidol and 4 mg ondansetron identified significant QTc interval prolongation (17 &plusmn; 9 ms droperidol, 20 &plusmn; 13ms ondansetron), with the QTc interval significantly lower after the 90th minute.</p><p>&nbsp;</p><p>A study looking at the combination of ondansetron (4 mg) and droperidol (1 mg) showed that both drugs increased QTc interval separately (17 &plusmn; 10 ms ondansetron, 25 &plusmn; 8 ms droperidol) but there was no additive effect when given together (28 &plusmn; 10 ms).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The action of a single intravenous dose commences 2-3 minutes following administration. The tranquillising and sedative effects tend to persist for 2 to 4 hours, although alertness may be affected for up to 12 hours.</p><p><strong>&nbsp;</strong></p><p><strong>Distribution</strong></p><p>Following intravenous administration, plasma concentrations fall rapidly during the first 15 minutes; this is metabolism independent, redistribution of the drug. Plasma protein binding amounts to 85 &ndash; 90 %. The distribution volume is approximately 1.5 l/kg.</p><p><strong>&nbsp;</strong></p><p><strong>Metabolism</strong></p><p>Droperidol is extensively metabolised in the liver, and undergoes oxidation, dealkylation, demethylation and hydroxylation by cytochrome P450 isoenzymes 1A2 and 3A4, and to a lesser extent by 2C 19. The metabolites are devoid of neuroleptic activity.</p><p><strong>&nbsp;</strong></p><p><strong>Elimination</strong></p><p>Elimination occurs mainly through metabolism; 75% is excreted via the kidneys. Only 1% of the active substance is excreted unchanged with urine, and 11% with faeces. Plasma clearance is 0.8 (0.4 - 1.8) l/min. The elimination half-life (t1/2&szlig;) is 134 &plusmn; 13 min.</p><p><strong>&nbsp;</strong></p><p><strong>Drug Interactions</strong></p><p>A study combining ondansetron (4 mg) and droperidol (1 mg) showed that when administered together there was no pharmacokinetic interaction between the two drugs.</p><p><strong>&nbsp;</strong></p><p><strong>Paediatric Population</strong></p><p>In a study of 12 children (age 3.5 to 12 years), the values for distribution volume and clearance reported were lower than those found in the adult population (0.58 &plusmn; 0.29 l/kg and 4.66 2.28 ml/kg*min respectively) and decrease in parallel. The elimination half-life (101.5 &plusmn; 26.4 min) was similar to that found in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxic or carcinogenic potential, and reproductive toxicity. A study of oral droperidol in rats showed no impairment of fertility in males or females at up to 20 times the maximum human dose.</p><p>&nbsp;</p><p>Electrophysiological <em>in vitro</em> and <em>in vivo</em> studies indicate an overall risk of droperidol to prolong the QT interval in humans.</p><p>&nbsp;</p><p>In humans, the free peak plasma concentration is approximately 4-fold higher to 25- fold lower than the droperidol concentrations affecting the endpoints examined in the different <em>in vitro</em> and <em>in vivo</em> test systems used to assess the impact of this drug on cardiac repolarisation. Plasma levels fall by about one order of magnitude over the first twenty minutes after administration.</p><p>&nbsp;</p><p><strong>Environmental Risk Assessment (ERA)</strong></p><p>This product is unlikely to represent a risk to the environment following its prescribed use in patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Tartaric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatible with barbiturates. This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened: 36 months.

After first opening: For immediate use.

After dilution: Chemical and physical in-use stability of 5 mg droperidol with 100 mg morphine sulphate in 50 ml of 0.9% sodium chloride has been demonstrated in plastic syringes for 14 days at 25°C. 

From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 ml type I amber glass ampoules with white colour break.</p><p>&nbsp;</p><p>Pack size: 10 Ampoules (2 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only. Any unused solution should be discarded.</p><p>&nbsp;</p><p>The solution should be inspected visually prior to use. Only clear and colourless solutions free from visible particles should be used.</p><p>&nbsp;</p><p>For use in PCA: Draw droperidol and morphine into a syringe and make up the volume with 0.9% sodium chloride for injection.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                29 January 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>